{
  "DOI": "10.1186/s40246-022-00445-5",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-022-00445-5",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eNovel biomarkers for personalizing anticoagulation remain undetermined. We aimed to investigate the association of plasma miRNAs with pharmacokinetic–pharmacodynamic (PK-PD) profiles of rivaroxaban.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eMethods\u003c/jats:title\u003e\n                \u003cjats:p\u003eThis is a multicenter, exploratory study of miRNAs in a Chinese population. Healthy volunteers and patients receiving rivaroxaban were enrolled in the study. The area under the plasma concentration–time curve from time 0-t h (AUC\u003cjats:sub\u003e0-t\u003c/jats:sub\u003e) and anti-Xa activity at 3 h (AXA\u003cjats:sub\u003e3h\u003c/jats:sub\u003e) were measured in healthy volunteers, and AXA\u003cjats:sub\u003e3h\u003c/jats:sub\u003e was measured in patients. MiRNAs were detected by miRNA microarray in 26 healthy volunteers with 20 mg rivaroxaban, and quantitative reverse transcription polymerase chain reaction was used to exclude undetectable ones. MiR-320a-3p and miR-483-5p were then quantified in 65 healthy volunteers and 71 patients. MiRNA levels at 3 h were compared between high and low AXA\u003cjats:sub\u003e3h\u003c/jats:sub\u003e or AUC\u003cjats:sub\u003e0-t\u003c/jats:sub\u003e subjects and in matched patients with or without bleeding during follow-up. The miRNA targets were predicted by TargetScan, miRTarBase, and miRDB. Validated genes were included in GO enrichment and KEGG analyses. The protein–protein interaction network was established by STRING and visualized by Cytoscape.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eA total of 136 Chinese subjects completed the study. In healthy volunteers taking 15 mg rivaroxaban, the miR-320a level at 3 h was significantly positively correlated with AXA\u003cjats:sub\u003e3h\u003c/jats:sub\u003e and AUC\u003cjats:sub\u003e0-t\u003c/jats:sub\u003e (\u003cjats:italic\u003er\u003c/jats:italic\u003e = 0.359, \u003cjats:italic\u003ep\u003c/jats:italic\u003e = 0.025; \u003cjats:italic\u003er\u003c/jats:italic\u003e = 0.370, \u003cjats:italic\u003ep\u003c/jats:italic\u003e = 0.02, respectively). A positive correlation was also observed between miR-483 and AXA\u003cjats:sub\u003e3h\u003c/jats:sub\u003e or AUC\u003cjats:sub\u003e0-t\u003c/jats:sub\u003e (\u003cjats:italic\u003er\u003c/jats:italic\u003e = 0.372, \u003cjats:italic\u003ep\u003c/jats:italic\u003e = 0.02; \u003cjats:italic\u003er\u003c/jats:italic\u003e = 0.523, \u003cjats:italic\u003ep\u003c/jats:italic\u003e = 0.001, respectively). MiR-320a and miR-483 levels at 3 h in the higher AUC\u003cjats:sub\u003e0-t\u003c/jats:sub\u003e group were significantly higher than those at 0 h. MiR-483 levels at 3 h may distinguish healthy volunteers with high or low AXA\u003cjats:sub\u003e3h\u003c/jats:sub\u003e or AUC\u003cjats:sub\u003e0-t\u003c/jats:sub\u003e. In the 10 mg fed subgroup, higher 3 h mir-483 levels were also observed compared with the control group. No significant differences were found in the comparisons among patients. Bioinformatic analysis showed that these miRNAs may play a regulatory role by targeting ABCG2, ITGB3, PTEN, MAPK1/3, etc.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusions\u003c/jats:title\u003e\n                \u003cjats:p\u003eMiR-320a and miR-483 levels were found to be associated with PK and PD profiles of rivaroxaban in healthy Chinese subjects. Further studies are required to verify these findings and explore the mechanisms.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "445"
  ],
  "article-number": "72",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "27 March 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "15 December 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "28 December 2022"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The protocol was approved by an independent ethics committee and the Institutional Review Board of Peking University First Hospital and all participating research subcentral hospitals. The trial registration number is NCT03161496. All subjects were enrolled in this study after signing informed consent."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "All authors of this paper consent for publishing the manuscript and figures in the journal."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "The authors declare that they have no competing interests."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Zhang",
      "given": "Hanxu",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Zhang",
      "given": "Zhuo",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Liu",
      "given": "Zhiyan",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Mu",
      "given": "Guangyan",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Xie",
      "given": "Qiufen",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Zhou",
      "given": "Shuang",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wang",
      "given": "Zhe",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cao",
      "given": "Yu",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Tan",
      "given": "Yunlong",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wei",
      "given": "Xiaohua",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Yuan",
      "given": "Dongdong",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Xiang",
      "given": "Qian",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cui",
      "given": "Yimin",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2022,
        12,
        28
      ]
    ],
    "date-time": "2022-12-28T08:03:14Z",
    "timestamp": 1672214594000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        12,
        28
      ]
    ],
    "date-time": "2022-12-28T09:08:17Z",
    "timestamp": 1672218497000
  },
  "funder": [
    {
      "award": [
        "No. 2017ZX09304028"
      ],
      "name": "National Science and Technology Major Projects for “Major New Drugs Innovation and Development” of China"
    },
    {
      "DOI": "10.13039/501100001809",
      "award": [
        "No. 81973395",
        "No. 81872940"
      ],
      "doi-asserted-by": "publisher",
      "name": "National Natural Science Foundation of China"
    },
    {
      "DOI": "10.13039/501100012166",
      "award": [
        "No. 2016YFC0904900"
      ],
      "doi-asserted-by": "publisher",
      "name": "National Key Research and Development Program of China"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2023,
        8,
        15
      ]
    ],
    "date-time": "2023-08-15T15:40:49Z",
    "timestamp": 1692114049810
  },
  "is-referenced-by-count": 2,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2022,
        12,
        28
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2022,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            12,
            28
          ]
        ],
        "date-time": "2022-12-28T00:00:00Z",
        "timestamp": 1672185600000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            12,
            28
          ]
        ],
        "date-time": "2022-12-28T00:00:00Z",
        "timestamp": 1672185600000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-022-00445-5.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-022-00445-5/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-022-00445-5.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2022,
        12,
        28
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2022,
        12,
        28
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1378/chest.11-2294",
      "doi-asserted-by": "crossref",
      "key": "445_CR1",
      "unstructured": "Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e120S–e51S."
    },
    {
      "DOI": "10.1378/chest.11-2292",
      "author": "W Ageno",
      "doi-asserted-by": "publisher",
      "first-page": "e44S",
      "issue": "2 Suppl",
      "journal-title": "Chest",
      "key": "445_CR2",
      "unstructured": "Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-e88S.",
      "volume": "141",
      "year": "2012"
    },
    {
      "key": "445_CR3",
      "unstructured": "Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022406s036,202439s036lbl.pdf. Accessed 31 Aug 2021."
    },
    {
      "DOI": "10.1016/j.clpt.2005.06.011",
      "author": "D Kubitza",
      "doi-asserted-by": "publisher",
      "first-page": "412",
      "journal-title": "Clin Pharmacol Ther",
      "key": "445_CR4",
      "unstructured": "Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412–21.",
      "volume": "78",
      "year": "2005"
    },
    {
      "DOI": "10.1007/s00228-005-0043-5",
      "author": "D Kubitza",
      "doi-asserted-by": "publisher",
      "first-page": "873",
      "journal-title": "Eur J Clin Pharmacol",
      "key": "445_CR5",
      "unstructured": "Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873–80.",
      "volume": "61",
      "year": "2005"
    },
    {
      "DOI": "10.1007/s40262-013-0100-7",
      "author": "W Mueck",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Clin Pharmacokinet",
      "key": "445_CR6",
      "unstructured": "Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1–16.",
      "volume": "53",
      "year": "2014"
    },
    {
      "DOI": "10.1111/jth.12165",
      "author": "MM Samama",
      "doi-asserted-by": "publisher",
      "first-page": "579",
      "journal-title": "J Thromb Haemost: JTH",
      "key": "445_CR7",
      "unstructured": "Samama MM. Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay. J Thromb Haemost: JTH. 2013;11:579–80.",
      "volume": "11",
      "year": "2013"
    },
    {
      "DOI": "10.5414/CPP45335",
      "author": "W Mueck",
      "doi-asserted-by": "publisher",
      "first-page": "335",
      "journal-title": "Int J Clin Pharmacol Ther",
      "key": "445_CR8",
      "unstructured": "Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban: an oral, direct factor xa inhibitor—in healthy subjects. Int J Clin Pharmacol Ther. 2007;45:335–44.",
      "volume": "45",
      "year": "2007"
    },
    {
      "DOI": "10.1016/j.thromres.2015.12.001",
      "author": "S Testa",
      "doi-asserted-by": "publisher",
      "first-page": "178",
      "journal-title": "Thromb Res",
      "key": "445_CR9",
      "unstructured": "Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res. 2016;137:178–83.",
      "volume": "137",
      "year": "2016"
    },
    {
      "DOI": "10.5772/intechopen.95966",
      "doi-asserted-by": "crossref",
      "key": "445_CR10",
      "unstructured": "Shnayder NA, Petrova MM, Shesternya PA, Savinova AV, Bochanova EN, Zimnitskaya OV, et al. Using pharmacogenetics of direct oral anticoagulants to predict changes in their pharmacokinetics and the risk of adverse drug reactions. Biomedicines. 2021;9."
    },
    {
      "DOI": "10.1007/s00109-011-0840-5",
      "author": "J Xu",
      "doi-asserted-by": "publisher",
      "first-page": "865",
      "journal-title": "J Mol Med (Berlin)",
      "key": "445_CR11",
      "unstructured": "Xu J, Zhao J, Evan G, Xiao C, Cheng Y, Xiao J. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berlin). 2012;90:865–75.",
      "volume": "90",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.cell.2007.12.024",
      "author": "A Eulalio",
      "doi-asserted-by": "publisher",
      "first-page": "9",
      "journal-title": "Cell",
      "key": "445_CR12",
      "unstructured": "Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008;132:9–14.",
      "volume": "132",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.cca.2020.01.034",
      "author": "AA Hembrom",
      "doi-asserted-by": "publisher",
      "first-page": "66",
      "journal-title": "Clin Chim Acta",
      "key": "445_CR13",
      "unstructured": "Hembrom AA, Srivastava S, Garg I, Kumar B. MicroRNAs in venous thrombo-embolism. Clin Chim Acta. 2020;504:66–72.",
      "volume": "504",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.jjcc.2019.05.018",
      "author": "S Komal",
      "doi-asserted-by": "publisher",
      "first-page": "475",
      "journal-title": "J Cardiol",
      "key": "445_CR14",
      "unstructured": "Komal S, Yin JJ, Wang SH, Huang CZ, Tao HL, Dong JZ, et al. MicroRNAs: emerging biomarkers for atrial fibrillation. J Cardiol. 2019;74:475–82.",
      "volume": "74",
      "year": "2019"
    },
    {
      "DOI": "10.1161/CIRCRESAHA.111.247452",
      "author": "EE Creemers",
      "doi-asserted-by": "publisher",
      "first-page": "483",
      "journal-title": "Circ Res",
      "key": "445_CR15",
      "unstructured": "Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483–95.",
      "volume": "110",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.pharmthera.2014.03.002",
      "author": "K Ikemura",
      "doi-asserted-by": "publisher",
      "first-page": "217",
      "journal-title": "Pharmacol Ther",
      "key": "445_CR16",
      "unstructured": "Ikemura K, Iwamoto T, Okuda M. MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier function. Pharmacol Ther. 2014;143:217–24.",
      "volume": "143",
      "year": "2014"
    },
    {
      "DOI": "10.1517/17425250903307448",
      "author": "AM Yu",
      "doi-asserted-by": "publisher",
      "first-page": "1513",
      "journal-title": "Expert Opin Drug Metab Toxicol",
      "key": "445_CR17",
      "unstructured": "Yu AM. Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opin Drug Metab Toxicol. 2009;5:1513–28.",
      "volume": "5",
      "year": "2009"
    },
    {
      "key": "445_CR18",
      "unstructured": "Janssen Pharmaceuticals, Inc. XARELTO® (rivaroxaban) tablets, for oral use [package insert]. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202439_S035_022406S037lbl.pdf. Accessed 4 Oct 2021."
    },
    {
      "DOI": "10.1016/j.thromres.2019.07.024",
      "author": "Q Xiang",
      "doi-asserted-by": "publisher",
      "first-page": "127",
      "journal-title": "Thromb Res",
      "key": "445_CR19",
      "unstructured": "Xiang Q, Zhang HX, Wang Z, Liu ZY, Xie QF, Hu K, et al. The predictive value of circulating microRNAs for venous thromboembolism diagnosis: a systematic review and diagnostic meta-analysis. Thromb Res. 2019;181:127–34.",
      "volume": "181",
      "year": "2019"
    },
    {
      "DOI": "10.1093/ejcts/ezw245",
      "author": "L Harling",
      "doi-asserted-by": "publisher",
      "first-page": "73",
      "journal-title": "Eur J Cardiothorac Surg",
      "key": "445_CR20",
      "unstructured": "Harling L, Lambert J, Ashrafian H, Darzi A, Gooderham NJ, Athanasiou T. Elevated serum microRNA 483–5p levels may predict patients at risk of post-operative atrial fibrillation. Eur J Cardiothorac Surg. 2017;51:73–8.",
      "volume": "51",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.bbrc.2014.10.064",
      "author": "M Xiang",
      "doi-asserted-by": "publisher",
      "first-page": "210",
      "journal-title": "Biochem Biophys Res Commun",
      "key": "445_CR21",
      "unstructured": "Xiang M, Zeng Y, Yang R, Xu H, Chen Z, Zhong J, et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 2014;454:210–4.",
      "volume": "454",
      "year": "2014"
    },
    {
      "DOI": "10.1111/j.1365-2141.2008.07077.x",
      "author": "CH Lawrie",
      "doi-asserted-by": "publisher",
      "first-page": "672",
      "journal-title": "Br J Haematol",
      "key": "445_CR22",
      "unstructured": "Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5.",
      "volume": "141",
      "year": "2008"
    },
    {
      "DOI": "10.1002/ijc.25007",
      "author": "Z Huang",
      "doi-asserted-by": "publisher",
      "first-page": "118",
      "journal-title": "Int J Cancer",
      "key": "445_CR23",
      "unstructured": "Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–26.",
      "volume": "127",
      "year": "2010"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-07-0666",
      "author": "TS Wong",
      "doi-asserted-by": "publisher",
      "first-page": "2588",
      "journal-title": "Clin Cancer Res",
      "key": "445_CR24",
      "unstructured": "Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008;14:2588–92.",
      "volume": "14",
      "year": "2008"
    },
    {
      "DOI": "10.1186/1479-5876-10-55",
      "author": "M Redova",
      "doi-asserted-by": "publisher",
      "first-page": "55",
      "journal-title": "J Transl Med",
      "key": "445_CR25",
      "unstructured": "Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55.",
      "volume": "10",
      "year": "2012"
    },
    {
      "DOI": "10.1126/science.aav1741",
      "doi-asserted-by": "crossref",
      "key": "445_CR26",
      "unstructured": "McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, et al. The biochemical basis of microRNA targeting efficacy. Science. 2019;366."
    },
    {
      "author": "HY Huang",
      "first-page": "D148",
      "journal-title": "Nucleic Acids Res",
      "key": "445_CR27",
      "unstructured": "Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 2020;48:D148–54.",
      "volume": "48",
      "year": "2020"
    },
    {
      "DOI": "10.1093/nar/gkz757",
      "author": "Y Chen",
      "doi-asserted-by": "publisher",
      "first-page": "D127",
      "journal-title": "Nucleic Acids Res",
      "key": "445_CR28",
      "unstructured": "Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48:D127–31.",
      "volume": "48",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41467-019-09234-6",
      "author": "Y Zhou",
      "doi-asserted-by": "publisher",
      "first-page": "1523",
      "journal-title": "Nat Commun",
      "key": "445_CR29",
      "unstructured": "Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.",
      "volume": "10",
      "year": "2019"
    },
    {
      "DOI": "10.1101/gr.1239303",
      "author": "P Shannon",
      "doi-asserted-by": "publisher",
      "first-page": "2498",
      "journal-title": "Genome Res",
      "key": "445_CR30",
      "unstructured": "Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.",
      "volume": "13",
      "year": "2003"
    },
    {
      "DOI": "10.1093/nar/gkaa1074",
      "author": "D Szklarczyk",
      "doi-asserted-by": "publisher",
      "first-page": "D605",
      "journal-title": "Nucleic Acids Res",
      "key": "445_CR31",
      "unstructured": "Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49:D605–12.",
      "volume": "49",
      "year": "2021"
    },
    {
      "DOI": "10.1186/1471-2105-4-2",
      "author": "GD Bader",
      "doi-asserted-by": "publisher",
      "first-page": "2",
      "journal-title": "BMC Bioinform",
      "key": "445_CR32",
      "unstructured": "Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2.",
      "volume": "4",
      "year": "2003"
    },
    {
      "DOI": "10.1186/1752-0509-8-S4-S11",
      "doi-asserted-by": "crossref",
      "key": "445_CR33",
      "unstructured": "Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8 Suppl 4(Suppl 4):S11."
    },
    {
      "DOI": "10.1016/j.envpol.2021.117584",
      "author": "K Berg",
      "doi-asserted-by": "publisher",
      "first-page": "117584",
      "journal-title": "Environ Pollut",
      "key": "445_CR34",
      "unstructured": "Berg K, Romer Present P, Richardson K. Long-term air pollution and other risk factors associated with COVID-19 at the census tract level in Colorado. Environ Pollut. 2021;287:117584.",
      "volume": "287",
      "year": "2021"
    },
    {
      "DOI": "10.1515/dmpt-2021-0118",
      "author": "E Rytkin",
      "doi-asserted-by": "publisher",
      "first-page": "41",
      "journal-title": "Drug Metab Personal Ther.",
      "key": "445_CR35",
      "unstructured": "Rytkin E, Bure IV, Bochkov PO, Akmalova KA, Mirzaev KB, Cherniaeva MS, et al. MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug Metab Personal Ther. 2021;37:41–6.",
      "volume": "37",
      "year": "2021"
    },
    {
      "DOI": "10.1253/circj.CJ-18-0506",
      "author": "S Wada",
      "doi-asserted-by": "publisher",
      "first-page": "2872",
      "journal-title": "Circ J",
      "key": "445_CR36",
      "unstructured": "Wada S, Toyoda K, Sato S, Matsuki T, Okata T, Kumamoto M, et al. Anti-Xa activity and event risk in patients with direct factor Xa inhibitors initiated early after stroke. Circ J. 2018;82:2872–9.",
      "volume": "82",
      "year": "2018"
    },
    {
      "DOI": "10.1111/jth.14457",
      "author": "S Testa",
      "doi-asserted-by": "publisher",
      "first-page": "1064",
      "journal-title": "J Thromb Haemost: JTH",
      "key": "445_CR37",
      "unstructured": "Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost: JTH. 2019;17:1064–72.",
      "volume": "17",
      "year": "2019"
    },
    {
      "author": "AY Lu",
      "first-page": "1217",
      "journal-title": "Drug Metab Dispos",
      "key": "445_CR38",
      "unstructured": "Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab Dispos. 1998;26:1217–22.",
      "volume": "26",
      "year": "1998"
    },
    {
      "DOI": "10.1016/j.apsb.2012.02.011",
      "author": "AM Yu",
      "doi-asserted-by": "publisher",
      "first-page": "93",
      "journal-title": "Acta Pharm Sin B",
      "key": "445_CR39",
      "unstructured": "Yu AM, Pan YZ. Noncoding microRNAs: small RNAs play a big role in regulation of ADME? Acta Pharm Sin B. 2012;2:93–101.",
      "volume": "2",
      "year": "2012"
    },
    {
      "DOI": "10.2174/1389450118666170125144557",
      "author": "P Manikandan",
      "doi-asserted-by": "publisher",
      "first-page": "38",
      "journal-title": "Curr Drug Targets",
      "key": "445_CR40",
      "unstructured": "Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38–54.",
      "volume": "19",
      "year": "2018"
    },
    {
      "DOI": "10.1007/s11095-009-9924-0",
      "author": "S Shugarts",
      "doi-asserted-by": "publisher",
      "first-page": "2039",
      "journal-title": "Pharm Res",
      "key": "445_CR41",
      "unstructured": "Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26:2039–54.",
      "volume": "26",
      "year": "2009"
    },
    {
      "DOI": "10.1002/path.4866",
      "author": "DW Kang",
      "doi-asserted-by": "publisher",
      "first-page": "614",
      "journal-title": "J Pathol",
      "key": "445_CR42",
      "unstructured": "Kang DW, Yang ES, Noh YN, Hwang WC, Jo SY, Suh YA, et al. MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting beta-catenin and ATP-binding cassette, subfamily G, member 2. J Pathol. 2017;241:614–25.",
      "volume": "241",
      "year": "2017"
    },
    {
      "DOI": "10.1124/mol.114.092759",
      "author": "DX He",
      "doi-asserted-by": "publisher",
      "first-page": "536",
      "journal-title": "Mol Pharmacol",
      "key": "445_CR43",
      "unstructured": "He DX, Gu XT, Jiang L, Jin J, Ma X. A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer. Mol Pharmacol. 2014;86:536–47.",
      "volume": "86",
      "year": "2014"
    },
    {
      "author": "YJ Guo",
      "first-page": "1997",
      "journal-title": "Exp Ther Med",
      "key": "445_CR44",
      "unstructured": "Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19:1997–2007.",
      "volume": "19",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.jss.2010.01.041",
      "author": "R Jiang",
      "doi-asserted-by": "publisher",
      "first-page": "319",
      "journal-title": "J Surg Res",
      "key": "445_CR45",
      "unstructured": "Jiang R, Wang NP, Tanaka KA, Levy JH, Guyton RA, Zhao ZQ, et al. Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-kappaB-dependent pathways. J Surg Res. 2011;169:319–27.",
      "volume": "169",
      "year": "2011"
    },
    {
      "DOI": "10.1172/JCI118938",
      "author": "FN Ko",
      "doi-asserted-by": "publisher",
      "first-page": "1493",
      "journal-title": "J Clin Invest",
      "key": "445_CR46",
      "unstructured": "Ko FN, Yang YC, Huang SC, Ou JT. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest. 1996;98:1493–501.",
      "volume": "98",
      "year": "1996"
    },
    {
      "DOI": "10.1536/ihj.15-112",
      "author": "T Hashikata",
      "doi-asserted-by": "publisher",
      "first-page": "544",
      "journal-title": "Int Heart J",
      "key": "445_CR47",
      "unstructured": "Hashikata T, Yamaoka-Tojo M, Namba S, Kitasato L, Kameda R, Murakami M, et al. Rivaroxaban inhibits angiotensin II-induced activation in cultured mouse cardiac fibroblasts through the modulation of NF-kappaB pathway. Int Heart J. 2015;56:544–50.",
      "volume": "56",
      "year": "2015"
    },
    {
      "DOI": "10.1007/s11239-013-1047-0",
      "author": "AA Memon",
      "doi-asserted-by": "publisher",
      "first-page": "348",
      "journal-title": "J Thromb Thrombolysis",
      "key": "445_CR48",
      "unstructured": "Memon AA, Sundquist K, Wang X, Svensson PJ, Sundquist J, Zoller B. Transforming growth factor (TGF)-beta levels and unprovoked recurrent venous thromboembolism. J Thromb Thrombolysis. 2014;38:348–54.",
      "volume": "38",
      "year": "2014"
    },
    {
      "DOI": "10.1309/AJCP7VO4HAIZYATP",
      "author": "S Shetty",
      "doi-asserted-by": "publisher",
      "first-page": "82",
      "journal-title": "Am J Clin Pathol",
      "key": "445_CR49",
      "unstructured": "Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134:82–5.",
      "volume": "134",
      "year": "2010"
    },
    {
      "DOI": "10.1007/s00109-015-1346-3",
      "author": "L Stefanini",
      "doi-asserted-by": "publisher",
      "first-page": "13",
      "journal-title": "J Mol Med (Berlin)",
      "key": "445_CR50",
      "unstructured": "Stefanini L, Bergmeier W. RAP1-GTPase signaling and platelet function. J Mol Med (Berlin). 2016;94:13–9.",
      "volume": "94",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.jbior.2015.06.001",
      "author": "GF Guidetti",
      "doi-asserted-by": "publisher",
      "first-page": "36",
      "journal-title": "Adv Biol Regul",
      "key": "445_CR51",
      "unstructured": "Guidetti GF, Canobbio I, Torti M. PI3K/Akt in platelet integrin signaling and implications in thrombosis. Adv Biol Regul. 2015;59:36–52.",
      "volume": "59",
      "year": "2015"
    },
    {
      "DOI": "10.1111/j.1538-7836.2009.03658.x",
      "author": "S Severin",
      "doi-asserted-by": "publisher",
      "first-page": "17",
      "journal-title": "J Thromb Haemost: JTH",
      "key": "445_CR52",
      "unstructured": "Severin S, Ghevaert C, Mazharian A. The mitogen-activated protein kinase signaling pathways: role in megakaryocyte differentiation. J Thromb Haemost: JTH. 2010;8:17–26.",
      "volume": "8",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.jvs.2013.02.240",
      "author": "CS Lim",
      "doi-asserted-by": "publisher",
      "first-page": "219",
      "journal-title": "J Vasc Surg",
      "key": "445_CR53",
      "unstructured": "Lim CS, Kiriakidis S, Sandison A, Paleolog EM, Davies AH. Hypoxia-inducible factor pathway and diseases of the vascular wall. J Vasc Surg. 2013;58:219–30.",
      "volume": "58",
      "year": "2013"
    },
    {
      "DOI": "10.1186/s12943-015-0344-y",
      "author": "L Sun",
      "doi-asserted-by": "publisher",
      "first-page": "96",
      "journal-title": "Mol Cancer",
      "key": "445_CR54",
      "unstructured": "Sun L, Liu B, Lin Z, Yao Y, Chen Y, Li Y, et al. MiR-320a acts as a prognostic factor and Inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3. Mol Cancer. 2015;14:96.",
      "volume": "14",
      "year": "2015"
    },
    {
      "DOI": "10.1007/s11033-014-3110-0",
      "author": "C Shang",
      "doi-asserted-by": "publisher",
      "first-page": "2521",
      "journal-title": "Mol Biol Rep",
      "key": "445_CR55",
      "unstructured": "Shang C, Zhang H, Guo Y, Hong Y, Liu Y, Xue Y. MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3. Mol Biol Rep. 2014;41:2521–7.",
      "volume": "41",
      "year": "2014"
    },
    {
      "DOI": "10.1161/ATVBAHA.110.216531",
      "author": "AM Fager",
      "doi-asserted-by": "publisher",
      "first-page": "2400",
      "journal-title": "Arterioscler Thromb Vasc Biol",
      "key": "445_CR56",
      "unstructured": "Fager AM, Wood JP, Bouchard BA, Feng P, Tracy PB. Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. Arterioscler Thromb Vasc Biol. 2010;30:2400–7.",
      "volume": "30",
      "year": "2010"
    },
    {
      "DOI": "10.3390/ijms21103485",
      "doi-asserted-by": "crossref",
      "key": "445_CR57",
      "unstructured": "Zhelankin AV, Vasiliev SV, Stonogina DA, Babalyan KA, Sharova EI, Doludin YV, et al. Elevated plasma levels of circulating extracellular miR-320a-3p in patients with paroxysmal atrial fibrillation. Int J Mol Sci. 2020;21."
    },
    {
      "DOI": "10.12659/MSM.906596",
      "author": "Z Jiang",
      "doi-asserted-by": "publisher",
      "first-page": "2031",
      "journal-title": "Med Sci Monit",
      "key": "445_CR58",
      "unstructured": "Jiang Z, Ma J, Wang Q, Wu F, Ping J, Ming L. Combination of circulating miRNA-320a/b and D-Dimer improves diagnostic accuracy in deep vein thrombosis patients. Med Sci Monit. 2018;24:2031–7.",
      "volume": "24",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.chest.2016.08.1462",
      "author": "BT Samuelson",
      "doi-asserted-by": "publisher",
      "first-page": "127",
      "journal-title": "Chest",
      "key": "445_CR59",
      "unstructured": "Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest. 2017;151:127–38.",
      "volume": "151",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.thromres.2016.04.019",
      "author": "K Martin",
      "doi-asserted-by": "publisher",
      "first-page": "40",
      "journal-title": "Thromb Res",
      "key": "445_CR60",
      "unstructured": "Martin K, Moll S. Direct oral anticoagulant drug level testing in clinical practice: a single institution experience. Thromb Res. 2016;143:40–4.",
      "volume": "143",
      "year": "2016"
    },
    {
      "DOI": "10.1007/s10147-017-1104-3",
      "author": "J Matsuzaki",
      "doi-asserted-by": "publisher",
      "first-page": "413",
      "journal-title": "Int J Clin Oncol",
      "key": "445_CR61",
      "unstructured": "Matsuzaki J, Ochiya T. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. Int J Clin Oncol. 2017;22:413–20.",
      "volume": "22",
      "year": "2017"
    },
    {
      "DOI": "10.1371/journal.pone.0167969",
      "author": "C Glinge",
      "doi-asserted-by": "publisher",
      "first-page": "e0167969",
      "journal-title": "PLoS ONE",
      "key": "445_CR62",
      "unstructured": "Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B, et al. Stability of circulating blood-based microRNAs—pre-analytic methodological considerations. PLoS ONE. 2017;12:e0167969.",
      "volume": "12",
      "year": "2017"
    },
    {
      "DOI": "10.1093/nar/gkv249",
      "author": "P Godard",
      "doi-asserted-by": "publisher",
      "first-page": "3490",
      "journal-title": "Nucleic Acids Res",
      "key": "445_CR63",
      "unstructured": "Godard P, van Eyll J. Pathway analysis from lists of microRNAs: common pitfalls and alternative strategy. Nucleic Acids Res. 2015;43:3490–7.",
      "volume": "43",
      "year": "2015"
    }
  ],
  "reference-count": 63,
  "references-count": 63,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-022-00445-5"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "16"
}